納米生物學(xué)及其應(yīng)用_第1頁(yè)
納米生物學(xué)及其應(yīng)用_第2頁(yè)
納米生物學(xué)及其應(yīng)用_第3頁(yè)
納米生物學(xué)及其應(yīng)用_第4頁(yè)
納米生物學(xué)及其應(yīng)用_第5頁(yè)
已閱讀5頁(yè),還剩24頁(yè)未讀 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

·亓立峰浙江加州國(guó)際納米技術(shù)研究院·前言:納米微粒概述·Part

I:納米藥物與靶向設(shè)計(jì)·Part

II:腫瘤納米分子影像與實(shí)時(shí)治療·Part

III:納米探針·前景展望What

is

Nano?Quantum

dots,

magnetic

NPFig1.

A

schemetic

of

nanoscale

materialPolymer

NPPhycoerythrin前言某種物質(zhì)或元素納米級(jí)別粒子:nano

Zinic;SiO2,nano

gold,CdSe/ZnS,Fe2O3,Polymer

NPDegradablePolymericmatrixnanospherenanocapsuleOily

or

aqueous

corePolymericmembrane前言化學(xué)法:(1)沉淀法/透析法把沉淀劑加入到鹽溶液中反應(yīng)后,(將沉淀熱處理)得到納米材料。其特點(diǎn)簡(jiǎn)單易行,但純度低,顆粒半徑大,聚合體納米粒子、氧化物。(2)微乳液法/乳液擴(kuò)散法兩種互不相溶的溶劑在表面活性劑的作用下形成乳液,在微泡中經(jīng)成核、聚結(jié)、團(tuán)聚、(熱處理)后得納米粒子。其特點(diǎn)粒子的單分散和界面性好,聚合體納米粒子、Ⅱ~Ⅵ族半導(dǎo)體納米粒子多用此法制備納米微粒制備方法前言納米粒子表征方法測(cè)

法測(cè)量功能適用的尺寸范圍使用的主要儀器離心沉降法等效直徑>25nm高速離心機(jī),分光光度計(jì)或暗場(chǎng)法光學(xué)系統(tǒng)氣體吸附法(容量法或重量法)比表面積尺寸:約1~10nm比表面積:0.1~1000m2/gBET吸附裝置或重量法裝置光散射法平均直徑>約3nm喇曼光譜儀X射線衍射峰寬法晶粒平均尺寸約<500nm常用于<50nmX射線衍射儀小角度X射線散射線晶粒平均尺寸約<100nmX射線衍射儀電子成像法(TEM)直接觀察粒子形貌并測(cè)量粒徑尺寸約>2nm透射電子顯微鏡掃描隧道顯微鏡法(STM)形貌與尺寸寬范圍掃描隧道顯微鏡粒徑分析粒徑分布粒徑分析儀熒光光譜法熒光圖譜熒光光譜儀These

newly

formed

tumor

vessels

areusually

abnormal

in

form

and

architecture.They

are

poorly-aligned

defectiveendothelial

cells

with

wide

fenestrations,lacking

a

smooth

muscle

layer,

orinnervation

with

a

wider

lumen,

andimpaired

functional

receptors

forangiotensin

II.

Furthermore,

tumor

tissues

usually

lack

effective

lymphatic

drainage.All

these

factors

will

lead

to

abnormalmolecular

and

fluid

transport

dynamicsespecially

for

macromolecular

drugs.“enhanced

permeability

and

retention(EPR)-effect”

of

macromolecules

andlipids

in

solid

tumors./wiki/Enhanced_Per

meability_and_Retention_effectEnhanced

permeability

and

retention(EPR)

effect.

Long-circulating

drugcarriers

(1),

penetrate

through

the

leakyNamely,

this

phenomenon

was

coinedpathological

vasculature

(2),

into

thetumor

interstitium

(3),

and

degradethere,

releasing

a

free

drug

(4)

andcreating

its

high

local

concentration.AAPS

Journal.

2007;9(2):Article

15.DOI:10.1208/aapsj0902015Nanoparticles

:

clinicaladministration

of

anticancerdrugs.Advantages:√

Controlled

and

targeteddelivery

of

the

drug√

Reduced

systemic

side

effects√

Facilitated

extravasation

intothe

tumor

cells

(EPR

effect:enhanced

permeability

andretention)√

High

capability

to

crossvarious

physiological

barriersFig.3

Size

and

zeta

potential

of

CNP

and

CNP-CuL.

Qi,

et

al,

Colloids

Surfaces

A:

Physicochem

Eng

Aspects

2004;

251:

183190

;

Carbohydrate

Research

2004;

2693-270050

mV96

mVCNP-Cu13

mVChitosanCNPCNP-CuCNPPanel

of

celllineCell

lineCytotoxicity

(IC50,μg/mL)Chitosan

CNP

CNP-CuLiverL-02na

na

naColon

cancerCalo3201200(±

28(±3)

14(±2)27)Gastric

cancerBGC8231200(±35)

21(±2)

8

(±1)Liver

cancerBEL74021200(±22)

15(±2)

6

(±1)Values

are

means

of

three

experiments,

standard

deviation

is

given

inparenthese=

not

active).L.

Qi,

et

al,

Bioorganic

&

Medicinal

Chemistry

Letters

2005;

15:

1357-1399Table

1.

Cytotoxic

activity

of

chitosan,

CNP

(mean

particle

size

=

40

nm),

andCNP-Cu

against

different

cell

linesFig.5

CNP-induced

changes

of

MMP

and

zeta

potential

of

membrane.

A:

Loss

of

MMPand

zeta

potential;

Histogram

of

untreated

cells

(B)

and

cells

treated

with

100

μg/mL

CNP(C)CNP

could

neutralize

the

negative

surface

charge

of

BEL7402

cells

so

as

todamage

the

cell

membrane.

The

strong

dissipation

in

MMP

suggestsapossible

disruption

of

mitochondrial

membrane

after

treated

with

CNP.L.

Qi,

et

al,

Eur.

J.

Cancer

2007;

43:184-93Fatty

acidControl

(μg/mg)CNP

group

(μg/mg)C14:029.93±2.0130.29±2.21C16:0216.5±13.73215.51±5.41C18:0255.61±14.86252.11±10.99C18:1142.62±8.52108.66±5.11aC18:2226.22±8.29195.78±4.54

aC20:412.97±1.469.87±0.45

aaP<0.01

vs

ControlTable

2

Effects

of

CNP

on

fatty

acid

composition

ofmembrane

phosphoric

lipid

from

BEL7402

cellsFig.

6

Lipid

peroxidation

measured

asthiobarbituric

acid

reactive

substances(TBARs)

production

of

BEL7402

cells

non-treated

or

treated

for

24

h

with

variousdoses

of

CNP.Increased

ROS

(Reactive

oxygen

species)production

and

LPO

degree,

decreasedunsaturated

fattyacid

indicatedthat

CNPexerted

membrane

penetration

activity

byinductionof

LPOGroupsBWincrease

(g)TW

(g)TIR

(%)Control1.54±0.562.95±0.46-Chitosan1.78±0.972.24±0.41b2440

nm

CNP2.40±0.441.13±0.22b6270

nm

CNP2.38±0.481.21±0.29b59100

nm

CNP1.96±0.851.92±0.46b35Cisplatin

-2.3±0.99

0.56±0.13bSide

effects

of

chemotherapy81Table

4

Effect

of

CNP

with

different

particle

sizeon

BEL7402

tumor

cell

growth

in

nude

mice

byoral

administration

(1

mg/kg/day)Fig.

7

Effects

ofadministration

routes

onantitumor

efficacy

of

CNPagainstSarcoma-180

subcutaneous

tumorformation

and

growth

in

ICR

mice

Imaging:

cancer

diagnostics,

staging,radiation

planning,

and

evaluation

oftherapy.

Standard

clinical

imaging

modalities:CT,

MRI,

ultrasound,

limitation

indetection

(

<

0.5

cm),

anddistinguishing

between

benign

andcancerous

tumors.

Molecular

imaging:

Multifunctionalnanoparticles:

MNP,

QDs,

gold

NP,drug

delivery

(siRNA,

DNA,

drug),nanothermotherapy,

photodynamictherapy.(b)

Fluorescencespectraof

mouse

skin

and

QDs

with

UV

excitation.

Due

to

the

largeStokes

shift

of

QDs,

their

fluorescence

signals

can

be

shifted

to

a

spectral

region

where

the

autofluorescence

is

reduced.

See

textfor

further

discussion.Size-tunable

light

emissionPhotostableSimultaneous

excitation

of

QDsLarge

Stokes

shiftFigure

13.

Schematic

illustration

of

a

multifunctional

quantum

dotcoated

with

amphiphilic

polymer.Fig.

14.

Schematic

diagram

showing

the

steps

of

siRNA-QD

in

membrane

binding,

cellular

entry,endosomal

escape,

capturing

by

RNA

binding

proteins,

loading

to

RNA-induced

silencingcomplexes

(RISC),

and

target

degradation.Fig.

16.

Schematic

drawing

of

the

hybrid

structure

of

QD

andamphipol

for

siRNA

delivery

and

real-time

imaging

in

live

cells.Qi

and

Gao,

ACS

nano,

2008,

2(7),

1403–1410,

2008Fig.

17

QD

loading

capacity

and

protection

of

siRNAmoleculesagainst

nuclease

degradation

determined

by

gel

electrophoresis.Qi

and

Gao,

ACS

nano,

2008,

2(7),

1403–1410Fig.

18

Gene

silencing

efficiency

of

siRNA

targeting

Her-2

using

QDPMAL

compared

with

the

classic

transfection

agents,

Lipofectamine

and

PEI.Qi

and

Gao,

ACS

nano,

2008,

2(7),

1403–1410納米分子造影劑產(chǎn)品1)3TP的癌癥診斷技術(shù),基于MRI的診斷乳腺癌、前列腺癌,區(qū)分惡性/良性,〉5mm瘤塊。主要以釓/氧化鐵為組分核磁納米造影劑Palatin技術(shù)公司2007年獲批準(zhǔn)新型造影劑neutrospec,neutrospec含有一個(gè)以锝為標(biāo)記的抗cd15單克隆抗體,可以選擇性的結(jié)合于參與免疫應(yīng)答的嗜中性粒細(xì)胞。neutrospec被注射入血后,可與感染部位存在的嗜中性粒細(xì)胞相結(jié)合,使這些細(xì)胞被放射性示蹤劑所標(biāo)記。Part

III:納米探針Fig.22

Modulating

signaling

pathways

and

probing

biological

interactions

withnanotopographyOligo**?*

?*

*Fig.

25.

Cytotoxicity

of

CNCdetermined

by

detection

ofLDH

release

from

BJ-5acells

cocultured

withextracts

of

CNC

for

72

h.Fig.

26Actin

localization

in

spreading

cells

with

timeControlCNCChitosan3

h3

d11

d3.2納米纖維轉(zhuǎn)染DNAFig.

27.

Human

embryonic

kidney

cell

line

(HEK

293T)

cultured

onSiNWs

(c)

with

and

(d)

without

PEI

treatment

prior

to

GFP

plasmiddeposition.

Yang

et.

al.

J.

AM.

CHEM.

SOC.2007,129,

7228-72293.3靶分子監(jiān)測(cè)納米探針Fig.

28.

Well-dispersed

antibody-nanoshell

conjugates

in

the

absence

of

analytepossess

a

well-defined

extinction

peak

in

the

near-IR.

In

the

presence

of

thecomplementary

analyte,

multiple

nanoshells

bind

to

the

analyte,

causingagglutination

and

acorresponding

reduction

in

the

extinction

peak.Methods

in

Molecular

Biology?

?

303NANOBIOTECHNOLOGYPROTOCOLSFig.

29.

Signal

detection

of

oligonucleotide-derivatized

NBCshybridized

with

complementary

Cy5

oligonucleotide.Methods

in

Molecular

Biology?

?

303NANOBIOTECHNOLOGYPROTOCOLS3.3納米金熒光檢測(cè)核苷酸序列Fig.

30.

Flow

chamber

setup

for

hybridization

and

visualization

of

fluorescence

signaon

the

nanoarray.

Optical

microscope

image

of

an

optical

fiber-bundle

based

nanoarray

containing

individual

300

nmdiameter

fibers;

(ii)

magnified

SEM

image

of

aregion

of

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論